Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 , or a combination of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 , or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 , or a combination of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 .
1. A method of treating or prophylactically treating a fracture in a subject, comprising administering to the subject a sustained-release formulation comprising one or both of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 .
2. The method of claim 1 , wherein the fracture is a non-traumatic fracture.
3. The method of claim 2 , wherein the fracture is a non-traumatic fracture of the spine or hip.
4. The method of claim 1 , wherein the formulation comprises 25-hydroxyvitamin D 3 .
5. The method of claim 4 , wherein formulation comprises an oral dosage form comprising the 25-hydroxyvitamin D 3 .
6. The method of claim 5 , wherein the oral dosage form is a capsule.
7. The method of claim 1 , wherein the sustained release formulation comprises 1 μg to 100 μg 25-hydroxyvitamin D.
8. The method of claim 7 , wherein the sustained release formulation comprises 1 μg to 50 μg 25-hydroxyvitamin D.
9. The method of claim 1 , wherein the subject has a renal disease, optionally, end stage renal disease (ESRD).
10. A method of slowing the development of a fracture in a subject, comprising administering to the subject a sustained-release formulation comprising one or both of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 .
11. The method of claim 9 , wherein the fracture is a non-traumatic fracture.
12. The method of claim 10 , wherein the fracture is a non-traumatic fracture of the spine or hip.
13. The method of claim 10 , wherein the formulation comprises 25-hydroxyvitamin D 3 .
14. The method of claim 10 , wherein formulation comprises an oral dosage form comprising the one or both of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 .
15. The method of claim 13 , wherein the oral dosage form is a capsule.
16. The method of claim 9 , wherein the sustained release formulation comprises 1 μg to 100 μg 25-hydroxyvitamin D.
17. The method of claim 16 , wherein the sustained release formulation comprises 1 μg to 50 μg 25-hydroxyvitamin D.
18. The method of claim 10 , wherein the subject has a renal disease, optionally, end stage renal disease (ESRD).